Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
Alopecia areata (AA) is an inflammatory autoimmune skin disease characterized by targeting of anagen hair follicles by the host immune system resulting in varying degrees of hair loss. Topical corticosteroids and topical contact allergens are commonly prescribed to treat AA; however, AA treatment guidelines are sparse, as is clinical evidence supporting the efficacy of current therapeutic options. As the AA pipeline fills in (e.g., Pfizer’s PF-6700841, Incyte’s Jakafi), this content will offer insights from real-world claims data into prescribing trends in AA to help new players seeking to better understand current treatment practices in AA and define the market niche for their emerging product.
Already a Client? Log in to access this report.
Ian is an analyst on the Infectious, Niche, and Rare Diseases team at Decision Resources Group, specializing in niche and rare diseases. Ian conducts primary and secondary research to gauge the market landscapes of these diseases, thoroughly analyzing disease etiology, current treatments, unmet need, and emerging therapies expected to impact their respective markets. He received his doctorate in biomedical sciences from the University of Massachusetts Medical School and his in cell & molecular biology from the Worcester Polytechnic Institute. Prior to joining Decision Resources Group, Dr. Love was an Instructor in the Department of Internal Medicine at Virginia Commonwealth University.